Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Karissa M JohnstonLauren PowellEvan PopoffLinda HarrisRobert CroopVladimir CoricGilbert L'ItalienPublished in: The Clinical journal of pain (2022)
The benefit-risk profiles of lasmiditan, rimegepant, and ubrogepant may improve clinical decision-making.